Kusatsu/Shiga, Japan — October 27, 2015 – Takara Bio Inc. announced that HF10 US Phase II clinical trial data will be presented at the 27th AACR-NCI-EORTC (American Association for Cancer Research, National Cancer Institute, European Organization for Research and Treatment of Cancer) international conference. It also will present results obtained from Phase I clinical trial conducted in the U.S.
【Outline of presentation】
|Name of conference||The 27th AACR-NCI-EORTC International Conference|
|Place||Hynes Convention Center (Boston, MA. the U.S.)|
|Date||12:30 to 15:30, November 8 (local time)|
|Program||Immune Response to Therapies|
|Title||Safety Profile and Tumor Response in Patients with Refractory Superficial Cancers Treated with HF10, an Oncolytic Replication-competent HSV-1-derived Intratumoral Injectable, as Monotherapy and Combined with Ipilimumab|
Interim analysis of Phase II clinical trial for oncolytic virus HF10 in the U.S.
There was no serious adverse reaction or adverse reaction ≥ Grade 3 attributable to HF10
At the end of first 12 weeks of 24 weeks of evaluation period, tumor shrinkking was observed in 6 in 24 evaluable subjects
Among these 6 subjects, tumor disappeared in 2 subjects (complete response)
The results will be also presented in the 53th Annual Meeting of Japan Society of Clinical Oncology scheduled on October 29 at Kyoto International Conference Center (Kyoto).
For oncolytic virus HF10, a Phase II clinical trial in the U.S. against melanoma, and a Phase I clinical trial in Japan against solid cancers such as melanoma and squamous carcinoma are under way. Takara Bio will continue the clinical development of HF10, targeting putting it commercial basis in fiscal 2018.